For oncological therapy, perceived high-risk patients with IDH-mutated gliomas, according to the studies by Pignatti et al. [19] and Buckner et al. [12] from the pre-molecular era, are often given adjuvant treatment upfront following surgery to minimize the risk for rapid tumor progression and relapse. Here, IDH2 is linked to central nervous system cancer.